Key result
Carpentier-Edwards Perimount aortic valves demonstrate ~19 years expected durability in middle-aged patients.
Why the study?
Does the Carpentier-Edwards Perimount bioprosthesis provide long-term valve durability in patients aged 50-65 years undergoing AVR?
Does the Carpentier-Edwards Perimount bioprosthesis provide long-term valve durability in patients aged 50-65 years undergoing AVR?
The Carpentier-Edwards Perimount bioprosthesis demonstrates an expected durability of 19 years in patients aged 50-65 years, supporting its use as a long-term option in this demographic.
May inform Perimount selection in 50-65-year-olds; leaves open need for randomized durability confirmation.
In patients aged 50-65 years undergoing AVR with the Carpentier-Edwards Perimount bioprosthesis, the expected valve durability was 19 years. Age was not a significant risk factor for SVD within this age group. Patient selection and attention to timing of reintervention may be determinants of long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Bourguignon et al. (2015) studied this question. The Carpentier-Edwards Perimount aortic valve demonstrated an expected durability of 19 years in patients aged 50-65 years without age-related risk for SVD.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: